Here in Oregon, the hospital occupancy rate for respiratory problems is now greater than it was during SARS2. Only good thing is that not as many people are leaving the hospitals in body bags.

As I understand it, patients are being treated for Cytokine Storm, not any virus. Isn't that correct?

Then why couldn't Cytodyn do a straight-up set of trials for the use of Leronlimab for Cytokine Storm?

Forget what caused the storm. If the indication is respiratory distress from whatever agent, Leronlimab is the answer.

Why can't that happen? (Besides the practicality of money presently.)